Literature DB >> 9438920

The inhibitory effect of glucose on growth hormone secretion is lost in obesity but not in hypertension.

P Limone1, S E Oleandri, P Ajmone Catt, S Grottoli, C Frangioni, E Avogadri, M Perrin, M R Valetto, M Maccario.   

Abstract

In obesity there is a clear reduction of both spontaneous and stimulated GH secretion. Furthermore, in obese patients the somatotrope responsiveness to provocative stimulation is selectively refractory to the inhibitory effect of glucose load. It has been hypothesized that hyperinsulinism of obese patients could play a role in the pathogenesis of these alterations. Aim of the present study was to verify the GH response to GHRH and the ability of glucose load to inhibit it in patients with essential hypertension in whom hyperinsulinism and insulin resistance are frequently present. To this goal, 7 patients with essential hypertension (HP, age, mean +/- SE: 29.6 +/- 2.4 yr, 3 females and 4 males, BMI: 21.7 +/- 1.2 kg/m2), 7 obese (OB, 4 females and 3 males, 31.9 +/- 4.1 yr, 35.6 +/- 2.0 kg/m2) and 7 normal subjects (NS, 4 females and 3 males, 28.3 +/- 3.9 yr, 21.0 +/- 1.6 kg/m2) underwent the following tests: GHRH (1 microgram/kg i.v. at time 0) alone and preceded by oral glucose load (OGTT, 100 g po at -45 min). Basal insulin levels were similar in HP and OB (11.3 +/- 0.5 and 12.7 +/- 2.2 microU/ml, respectively); these, in turn, were higher (p < 0.005) than those in NS (6.8 +/- 0.8 microU/ml). Basal plasma glucose levels in HP were similar to those in OB and NS (80.3 +/- 3.6, 86.9 +/- 6.7 and 84.4 +/- 1.7 mg/dl, respectively). In HP and OB and NS basal GH (1.0 +/- 0.5, 1.0 +/- 0.6 and 0.3 +/- 0.1 micrograms/l, respectively) and IGF-I levels (132.6 +/- 14.8, 137.3 +/- 13.2 and 138.8 +/- 12.2 micrograms/l, respectively) were similar. In HP the GH response to GHRH (AUC: 1058.8 +/- 347.8 micrograms/l/min) was similar to that observed in NS (959.0 +/- 167.8 micrograms/l/min) and higher than that in OB (344.8 +/- 67.2 micrograms/l/min, p < 0.01). OGTT clearly blunted (p < 0.01) the GHRH-induced GH response in HP as well as in NS (401.8 +/- 104.4 and 521.6 +/- 76.6 (g/l/min, respectively) but not in OB (387.4 +/- 78.8 (g/l/min). The OGTT-induced insulin levels in HP did not differ from those of OB, both being higher (p < 0.05) than those recorded in NS. Glucose levels after OGTT were similar in the three groups. In conclusion, this study demonstrates that, like in normal subjects but differently from in obese patients the GH response to GHRH is normal in patients with essential hypertension and it is normally inhibited by oral glucose load even when these patients show high insulin levels. Thus, it is unlikely that the low somatotrope secretion and its refractoriness to inhibition by glucose load in obesity is due to hyperinsulinism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9438920     DOI: 10.1007/bf03346919

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  22 in total

1.  The effect of intravenous glucose infusion on the exercise-induced serum growth hormone rise in normals and juvenile diabetics.

Authors:  A P Hansen
Journal:  Scand J Clin Lab Invest       Date:  1971-10       Impact factor: 1.713

2.  Additive effects of growth hormone releasing factor and insulin hypoglycaemia on growth hormone release in man.

Authors:  M D Page; H P Koppeschaar; C A Edwards; C Dieguez; M F Scanlon
Journal:  Clin Endocrinol (Oxf)       Date:  1987-05       Impact factor: 3.478

3.  Reduced growth hormone response to growth hormone-releasing hormone in children with simple obesity: evidence for somatomedin-C mediated inhibition.

Authors:  S Loche; M Cappa; P Borrelli; A Faedda; A Crinò; S G Cella; R Corda; E E Müller; C Pintor
Journal:  Clin Endocrinol (Oxf)       Date:  1987-08       Impact factor: 3.478

Review 4.  Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.

Authors:  R A DeFronzo; E Ferrannini
Journal:  Diabetes Care       Date:  1991-03       Impact factor: 19.112

5.  Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.

Authors:  F Cordido; C Dieguez; F F Casanueva
Journal:  J Clin Endocrinol Metab       Date:  1990-05       Impact factor: 5.958

6.  Free insulin-like growth factors in human obesity.

Authors:  J Frystyk; E Vestbo; C Skjaerbaek; C E Mogensen; H Orskov
Journal:  Metabolism       Date:  1995-10       Impact factor: 8.694

7.  Oral glucose inhibits growth hormone secretion induced by human pancreatic growth hormone releasing factor 1-44 in normal man.

Authors:  R R Davies; S Turner; D G Johnston
Journal:  Clin Endocrinol (Oxf)       Date:  1984-10       Impact factor: 3.478

8.  Circulating insulin-like growth factor I concentrations in clinically severe obese patients with and without NIDDM in response to weight loss.

Authors:  J E Poulos; N Leggett-Frazier; P Khazanie; S Long; R Sportsman; K MacDonald; J F Caro
Journal:  Horm Metab Res       Date:  1994-10       Impact factor: 2.936

9.  In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.

Authors:  M Maccario; M Procopio; S Grottoli; S E Oleandri; P Razzore; F Camanni; E Ghigo
Journal:  J Clin Endocrinol Metab       Date:  1995-12       Impact factor: 5.958

10.  The effect of glucose on growth hormone (GH)-releasing hormone-mediated GH secretion in man.

Authors:  A Masuda; T Shibasaki; M Nakahara; T Imaki; Y Kiyosawa; K Jibiki; H Demura; K Shizume; N Ling
Journal:  J Clin Endocrinol Metab       Date:  1985-03       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.